Month: February 2023

DCN Dx and Mapp Biopharmaceutical Announce Subcontract

02/13/2023

Addressing the Need for the Rapid Non-subjective, Digitized Detection of Ebola and Ebola Family Viruses Excerpt from the Press Release: CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ — DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, today announced a subcontract with Mapp Biopharmaceutical, Inc., a developer of novel pharmaceuticals…

Read More

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

02/13/2023

Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / February 1, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that two IND-enabling toxicology studies have been completed in non-human primates (NHPs) using its lead bifunctional therapeutic candidate. SON-1210 is a proprietary, bispecific…

Read More

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

02/10/2023

Expects to Commence Phase 2a of CAReS During the First Quarter of 2023 Excerpt from the Press Release: SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that enrollment in…

Read More

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

02/10/2023

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen’s pipeline Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing…

Read More

First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors

02/10/2023

Dosing marks first time a computationally designed monoclonal antibody enters human trial in the U.S. U.S. enrollment begins in North Carolina, with additional sites being planned nationwide Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that…

Read More

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

02/09/2023

Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Feb. 2, 2023 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as…

Read More

Center for Breakthrough Medicines Launches Precision Plasmids™ Manufacturing to Accelerate Advanced Therapies into the Clinic

02/09/2023

Superior quality Precision Plasmids™ expedite clinical trial timelines with no wait time to start manufacturing custom plasmids Excerpt from the Press Release: KING OF PRUSSIA, Pa., Feb. 2, 2023 /PRNewswire/ — The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO), has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate…

Read More

Via Scientific, Inc., A New Cambridge Based Technology and AI Company Emerges from Stealth and Launches Groundbreaking Multi-Omics Analytics Platform

02/09/2023

Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 2, 2023 /PRNewswire/ — Via Scientific, Inc., a new Cambridge based technology and AI company, is proud to announce the launch of Foundry, a multi-omics accelerator platform focused on significantly shortening the path to scientific breakthroughs. The Foundry platform was originally developed at UMass Chan Medical School;…

Read More

Frontera Therapeutics Doses First Patient in a Clinical Trial of FT-003 Gene Therapy for the Treatment of Wet AMD

02/08/2023

Excerpt from the Press Release: BEDFORD, Mass. and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) — Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial…

Read More

New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care

02/08/2023

BeiGene Releases Report and Launches CancerandMentalHealth.com in Conjunction with World Cancer Day to Help Patients and Caregivers Overcome Barriers to Access Excerpt from the Press Release: BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer patients and caregivers…

Read More